Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (49)	7/27/1999 3:34:00 PM
From: LLCF	Read Replies (1) \| Respond to of 427

Off the top of my head here are a few that will have large option related hedges on, and therefore the shorts arent necessarily really short: CHIR, QGENF, AZA, CNTO, GILD, ALKS, LGND [warrants] May be others, I'd have to go through the list if anyone cares... DAK

To: Biomaven who wrote (49)	7/27/1999 3:39:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 427

My type of company doesn't usually attract a short position. However, the shorts wander into "an AGPH" on occasion, I guess. In that situation, I find that it's good to just keep shaking your leg....... they eventually fall off, suffering a scrape or two. Irritating little suckers, for awhile.

To: Biomaven who wrote (49)	7/29/1999 1:44:00 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 427

Peter, it seems incredible that some of my favorite biotechs are heavily shorted: BGEN, CLTR, BCHE, etc... I own Biogen and Coulter shares and am surprised particularly by the CLTR short position: it seems sure to take off as the company is set to begin making real money in a few months when Bexxar is approved. Biogen has seen a pretty nice run, so that is not as surprising that a short position is established, but the size is larger that I would have expected. Genzyme is a solid company, but a very slow grower and, while it is a biotech company, is laden with 1.a surgical product division that shows up as a big asset on the balance sheet but contributes little to the bottom line and 2. financing the spin-offs while they make their long way to profitability (hopefully). A large short position here doesn't surprise me. The short positions in so many promising smaller biotechs is nuts. Thanks for starting this thread and putting such interesting stuff here. Harold